Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACRS Aclaris Therapeutics	$1.75 -3.3%	$1.57	$1.05 ▼ $5.17	$189.58M	0.3	975,915 shs	260,116 shs
HRTX Heron Therapeutics	$1.32 +1.5%	$1.88	$1.04 ▼ $2.68	$202.35M	1.15	1.69 million shs	1.07 million shs
KPTI Karyopharm Therapeutics	$6.02 -7.4%	$4.46	$3.51 ▼ $16.95	$52.19M	0.28	127,638 shs	88,331 shs
LYEL Lyell Immunopharma	$10.65	$10.25	$7.65 ▼ $32.40	$204.59M	-0.19	83,443 shs	35,166 shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACRS Aclaris Therapeutics	+1.12%	+6.47%	+10.37%	+43.65%	+44.80%
HRTX Heron Therapeutics	+0.78%	-7.14%	-32.29%	-30.48%	-31.22%
KPTI Karyopharm Therapeutics	+4.50%	+46.07%	+61.69%	+40.09%	-45.14%
LYEL Lyell Immunopharma	-1.66%	-1.66%	+12.22%	+26.07%	-63.28%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACRS Aclaris Therapeutics	2.736 of 5 stars	3.6	3.0	0.0	2.1	1.7	0.6
HRTX Heron Therapeutics	4.2742 of 5 stars	3.2	1.0	4.2	4.2	3.3	0.6
KPTI Karyopharm Therapeutics	3.8881 of 5 stars	3.4	0.0	4.6	2.5	2.5	0.6
LYEL Lyell Immunopharma	3.2544 of 5 stars	2.8	5.0	0.0	0.8	4.2	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACRS Aclaris Therapeutics	3.11	Buy	$8.71	397.96% Upside
HRTX Heron Therapeutics	2.33	Hold	$4.50	240.91% Upside
KPTI Karyopharm Therapeutics	2.80	Moderate Buy	$34.00	464.78% Upside
LYEL Lyell Immunopharma	1.50	Reduce	$15.00	40.85% Upside

Current Analyst Ratings Breakdown

Latest KPTI, HRTX, LYEL, and ACRS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/12/2025	HRTX Heron Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong Sell
8/12/2025	KPTI Karyopharm Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$42.00 ➝ $25.00
8/8/2025	HRTX Heron Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$4.00 ➝ $3.00
7/16/2025	KPTI Karyopharm Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral
7/11/2025	KPTI Karyopharm Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$27.00
7/10/2025	ACRS Aclaris Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$6.00
6/25/2025	ACRS Aclaris Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00
6/24/2025	LYEL Lyell Immunopharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$10.00
6/23/2025	ACRS Aclaris Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$8.00
6/9/2025	HRTX Heron Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$6.00
5/28/2025	ACRS Aclaris Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$8.00

(Data available from 8/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACRS Aclaris Therapeutics	$18.72M	10.13	N/A	N/A	$1.22 per share	1.43
HRTX Heron Therapeutics	$149.69M	1.35	N/A	N/A	($0.18) per share	-7.33
KPTI Karyopharm Therapeutics	$145.24M	0.36	N/A	N/A	($27.55) per share	-0.22
LYEL Lyell Immunopharma	$60K	3,409.78	N/A	N/A	$15.56 per share	0.68

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACRS Aclaris Therapeutics	-$132.07M	-$1.37	N/A	N/A	N/A	-802.03%	-34.01%	-24.18%	11/5/2025 (Estimated)
HRTX Heron Therapeutics	-$13.58M	-$0.02	N/A	N/A	N/A	-0.62%	N/A	-0.40%	N/A
KPTI Karyopharm Therapeutics	-$76.42M	-$14.59	N/A	N/A	N/A	-90.02%	N/A	-84.28%	11/4/2025 (Estimated)
LYEL Lyell Immunopharma	-$342.99M	-$24.29	N/A	N/A	N/A	-552,328.31%	-85.58%	-68.85%	11/6/2025 (Estimated)

Latest KPTI, HRTX, LYEL, and ACRS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	LYEL Lyell Immunopharma	-$3.80	-$2.89	+$0.91	-$2.89	$0.00 million	$0.01 million
8/11/2025	Q2 2025	KPTI Karyopharm Therapeutics	-$3.80	-$4.32	-$0.52	-$4.32	$37.92 million	$37.93 million
8/8/2025	Q2 2025	HRTX Heron Therapeutics	-$0.01	-$0.02	-$0.01	-$0.02	$38.08 million	$37.20 million
8/7/2025	Q2 2025	ACRS Aclaris Therapeutics	-$0.13	-$0.13	N/A	-$0.13	$1.34 million	$1.78 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACRS Aclaris Therapeutics	N/A	N/A	N/A	N/A	N/A
HRTX Heron Therapeutics	N/A	N/A	N/A	N/A	N/A
KPTI Karyopharm Therapeutics	N/A	N/A	N/A	N/A	N/A
LYEL Lyell Immunopharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACRS Aclaris Therapeutics	N/A	3.88	3.88
HRTX Heron Therapeutics	N/A	0.82	0.53
KPTI Karyopharm Therapeutics	N/A	0.99	0.94
LYEL Lyell Immunopharma	N/A	7.65	7.65

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACRS Aclaris Therapeutics	98.34%
HRTX Heron Therapeutics	80.01%
KPTI Karyopharm Therapeutics	66.44%
LYEL Lyell Immunopharma	66.05%

Insider Ownership

Company	Insider Ownership
ACRS Aclaris Therapeutics	5.60%
HRTX Heron Therapeutics	5.86%
KPTI Karyopharm Therapeutics	2.98%
LYEL Lyell Immunopharma	22.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACRS Aclaris Therapeutics	100	108.33 million	102.27 million	Optionable
HRTX Heron Therapeutics	300	153.29 million	144.31 million	Optionable
KPTI Karyopharm Therapeutics	380	8.67 million	8.41 million	Optionable
LYEL Lyell Immunopharma	270	19.21 million	14.93 million	Optionable

KPTI, HRTX, LYEL, and ACRS Headlines

Recent News About These Companies

Lyell Immunopharma (NASDAQ:LYEL) Cut to Strong Sell at Wall Street Zen

August 17, 2025 | marketbeat.com

Lyell Immunopharma (NASDAQ:LYEL) Announces Quarterly Earnings Results

August 14, 2025 | marketbeat.com

Lyell Immunopharma Advances CAR T-Cell Therapies

August 14, 2025 | msn.com

Lyell Immunopharma trading resumes

August 13, 2025 | msn.com

Lyell Immunopharma trading halted, volatility trading pause

August 13, 2025 | msn.com

Lyell Immunopharma, Inc: Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2025

August 13, 2025 | finanznachrichten.de

Lyell Immunopharma files to sell 3.75M shares of common stock for holders

August 13, 2025 | msn.com

Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2025

August 12, 2025 | globenewswire.com

Lyell Immunopharma (LYEL) Projected to Post Quarterly Earnings on Wednesday

July 31, 2025 | marketbeat.com

Equity Insider: Biotech Underdogs Line Up for Pivotal Shots at Game-Changing Cancer Treatments

July 30, 2025 | finanznachrichten.de

Lyell Immunopharma (LYEL) Stock Soars Following Private Placement Announcement

July 25, 2025 | financialbuzz.comF

Lyell Immunopharma Shares Rise After Private Placement of Up to $100M

July 25, 2025 | marketwatch.com

Lyell Immunopharma Announces up to $100 Million Equity Private Placement

July 25, 2025 | globenewswire.com

Lyell: 'Hold' Rating Based On Phase 3 LYL314 LBCL Treatment Program Advancement

July 23, 2025 | seekingalpha.com

Lyell Immunopharma, Inc. (LYEL) Balance Sheet - Yahoo Finance

July 15, 2025 | finance.yahoo.com

Neoadjuvant Therapy in Triple-Negative Breast Cancer: Current Landscape and Emerging Therapies

July 15, 2025 | emjreviews.comE

Lyell Immunopharma to Participate in the H.C. Wainwright "HCW@Home" Series

June 23, 2025 | tmcnet.com

Lyell Immunopharma to Discuss Clinical Data on LYL314 at H.C. Wainwright's "HCW@Home" Series

June 23, 2025 | quiverquant.comQ

Lyell Immunopharma to Participate in the H.C. Wainwright “HCW@Home” Series

June 23, 2025 | globenewswire.com

Lyell Immunopharma Releases Data From Phase I/II Trial of CD19/20 Dual Targeting CAR T-Cell Therapy

June 20, 2025 | precisionmedicineonline.comP

Lyell reports new clinical data from trial of large B-cell lymphoma therapy

June 18, 2025 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

KPTI, HRTX, LYEL, and ACRS Company Descriptions

Aclaris Therapeutics NASDAQ:ACRS

$1.75 -0.06 (-3.31%)

Closing price 04:00 PM Eastern

Extended Trading

$1.80 +0.05 (+2.86%)

As of 07:37 PM Eastern

Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

Heron Therapeutics NASDAQ:HRTX

$1.32 +0.02 (+1.54%)

Closing price 04:00 PM Eastern

Extended Trading

$1.32 -0.01 (-0.38%)

As of 06:27 PM Eastern

Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.

Karyopharm Therapeutics NASDAQ:KPTI

$6.02 -0.48 (-7.38%)

Closing price 04:00 PM Eastern

Extended Trading

$6.46 +0.44 (+7.33%)

As of 07:41 PM Eastern

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.

Lyell Immunopharma NASDAQ:LYEL

$10.65 0.00 (0.00%)

Closing price 04:00 PM Eastern

Extended Trading

$10.66 +0.01 (+0.14%)

As of 04:10 PM Eastern

Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic. It is also developing LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T cell product candidate that is in Phase 1 clinical trial for the treatment of various solid tumors; and LYL845, a novel epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate, which is in Phase 1 clinical trial targeting multiple solid tumor indications. In addition, the company's preclinical product candidates include LYL119, a ROR1 CAR T-cell product for the treatment of enhanced cytotoxicity; and second generation TIL product. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time